STC2759

STC2759 is a preclinical-stage small molecule candidate being developed by Staidson Pharma (specifically through its Staidson Hongkong subsidiary) for the treatment of hyperuricemia. Hyperuricemia is a metabolic condition characterized by abnormally high levels of uric acid in the blood, which serves as the primary precursor to gout and is associated with various renal and cardiovascular comorbidities. While the specific molecular target of STC2759 has not been publicly disclosed on the company's pipeline, small molecules in this therapeutic area typically function as uricosuric agents (inhibiting renal reabsorption of uric acid) or xanthine oxidase inhibitors (reducing uric acid production). As of early 2024, the program remains in the preclinical phase of development.